Biofrontera Inc. (BFRIW) company profile
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
About Biofrontera
Pharmaceutical Preparations, SIC 2834
Biofrontera Inc. is a biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical treatments for dermatological conditions, focusing on photodynamic therapy. Its primary product line comprises Ameluz, a prescription drug, and the RhodoLED series of illumination lamps, including BF-RhodoLED and RhodoLED XL. Together, these products are used to treat actinic keratosis, a pre-cancerous skin condition, on the face and scalp. In addition to commercializing these products, the company conducts research and development focused on expanding approved indications. Biofrontera sells its products directly to dermatology offices and groups using a buy-and-bill distribution model.
The company operates primarily in the United States and has an international footprint that includes clinical research activities. As of late 2025, its workforce totals 92 employees, with 75 located in the United States and 19 based in Germany. Biofrontera Inc. maintains its principal executive offices and corporate headquarters in Woburn, Massachusetts.
Summary of the business section of Biofrontera's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biofrontera Inc.
- Founded
- 2015
- Headquarters
- Woburn, MA
- Address
- 120 Presidential Way,, Suite 330 01801
- Phone
- (781) 245-1325
- Website
- biofrontera-us.com
- Employees
- 92, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Morristown, New Jersey
Stock & identifiers
- Ticker
- BFRIW
- Other tickers
- BFRI
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2021
- Shares outstanding
- 15M, Aug 11, 2026
- Public float
- $6.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Jul 5, 2023
- SEC CIK
- 1858685
- CUSIP
- 09077D118
- ISIN
- US09077D1182
- FIGI
- BBG013841CP0
- LEI
- 984500444S8BE1EF0179
- EIN
- 47-3765675
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hermann Luebbert | CEO & Chairman, Director | 352,711 |
| Eugene Frederick Leffler | Chief Financial Officer | 206,250 |
| George Patrick Jones | Chief Commercial Officer | – |
| Beth J. Hoffman | Director | – |
| Kevin Daniel Weber | Director | – |
| Heikki Lanckriet | Director | – |
| John J. Borer Iii | Director | – |
| la Huerta Martinez Maria del Pilar de | Director | 400,000 |
| AG Biofrontera | Director | 400,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Hermann Luebbert Chairman and Chief Executive Officer | $489.68K | $192.54K | $112.63K | $73.13K | $5.26K | $873.23K | -33% |
| Fred Leffler Chief Financial Officer | $371.00K | $89.78K | $56.31K | $36.56K | $551 | $554.21K | -33% |
| George Jones Chief Commercial Officer | $96.92K | – | $60.50K | – | $213 | $157.64K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 1, 2021
- Offer price
- $5.00
- Securities offered
- 3,600,000
- Gross proceeds
- $18.00M
- Exchange
- Nasdaq
- First trading day
- Oct 29, 2021
- First-day close
- $4.41-11.8%
- Lock-up ends (est.)
- Apr 27, 2022
“The initial public offering price per unit is $5.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“of December 31, 2025, the Company had a total of 92 employees comprised of 75 employees (72 full-time and three part-time) in”
Corporate history
Events identified from SEC filings